{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:40:28Z","timestamp":1777952428214,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017425","name":"Pr\u00f3-Reitoria de Pesquisa e P\u00f3s-Gradua\u00e7\u00e3o, Universidade Federal do Par\u00e1","doi-asserted-by":"publisher","award":["Pr\u00f3-Reitoria de Pesquisa e P\u00f3s-Gradua\u00e7\u00e3o, Universidade Federal do Par\u00e1"],"award-info":[{"award-number":["Pr\u00f3-Reitoria de Pesquisa e P\u00f3s-Gradua\u00e7\u00e3o, Universidade Federal do Par\u00e1"]}],"id":[{"id":"10.13039\/100017425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00280-024-04689-x","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T06:01:35Z","timestamp":1718690495000},"page":"387-395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Alterations in pharmacogenetic genes and their implications for imatinib resistance in Chronic Myeloid Leukemia patients from an admixed population"],"prefix":"10.1007","volume":"94","author":[{"given":"Karla Beatriz Cardias","family":"Cereja-Pantoja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tereza Cristina","family":"de Brito Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lui Wallacy Morikawa Souza","family":"Vinagre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-8135","authenticated-orcid":false,"given":"Francisco Cezar Aquino","family":"de Moraes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna Gilioli","family":"da Costa Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Monte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang\u00e9lica Leite","family":"de Alc\u00e2ntara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Cohen-Paes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne Rodrigues","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidney Emanuel","family":"Batista dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Pimentel","family":"de Assump\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c2ndrea Kely","family":"Ribeiro dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rommel Mario Rodr\u00edguez","family":"Burbano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel Cruz","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Carracedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ney Pereira","family":"Carneiro dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"4689_CR1","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MWN, Silver RT, Goldman JM, Stone RM et al (2006) Five-year follow-up of patients receiving Imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417. https:\/\/doi.org\/10.1056\/NEJMoa062867","journal-title":"N Engl J Med"},{"key":"4689_CR2","unstructured":"Drugs@FDA FDA-Approved Drugs Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=021588 (accessed on 21 July 2023)."},{"key":"4689_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-91439-8_1","volume":"212","author":"CF Waller","year":"2018","unstructured":"Waller CF (2018) Imatinib Mesylate. Recent Results Cancer Res Fortschr Krebsforsch Progres Dans Rech Sur Cancer 212:1\u201327. https:\/\/doi.org\/10.1007\/978-3-319-91439-8_1","journal-title":"Recent Results Cancer Res Fortschr Krebsforsch Progres Dans Rech Sur Cancer"},{"key":"4689_CR4","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1016\/s2352-3026(15)00072-1","volume":"2","author":"JF Apperley","year":"2015","unstructured":"Apperley JF (2015) CML and Tyrosine kinase inhibition: the Hope becomes reality. Lancet Haematol 2:e176\u2013e177. https:\/\/doi.org\/10.1016\/s2352-3026(15)00072-1","journal-title":"Lancet Haematol"},{"key":"4689_CR5","doi-asserted-by":"publisher","unstructured":"Kang Z-J, Liu Y-F, Xu L-Z, Long Z-J, Huang D, Yang Y, Liu B, Feng J-X, Pan Y-J, Yan J-S et al (2016) The Philadelphia chromosome in Leukemogenesis. Chin J Cancer 35. https:\/\/doi.org\/10.1186\/s40880-016-0108-0","DOI":"10.1186\/s40880-016-0108-0"},{"key":"4689_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2217\/pgs-2017-0193","volume":"19","author":"R Ankathil","year":"2018","unstructured":"Ankathil R, Azlan H, Dzarr AA, Baba AA (2018) Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update. Pharmacogenomics 19:475\u2013393. https:\/\/doi.org\/10.2217\/pgs-2017-0193","journal-title":"Pharmacogenomics"},{"key":"4689_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.18553\/jmcp.2007.13.s8-a.8","volume":"13","author":"C Fausel","year":"2007","unstructured":"Fausel C (2007) Targeted chronic myeloid leukemia therapy: seeking a cure. J Manag Care Pharm JMCP 13:8\u201312. https:\/\/doi.org\/10.18553\/jmcp.2007.13.s8-a.8","journal-title":"J Manag Care Pharm JMCP"},{"key":"4689_CR8","doi-asserted-by":"publisher","first-page":"693609","DOI":"10.3389\/fimmu.2021.693609","volume":"12","author":"B Zhou","year":"2021","unstructured":"Zhou B, Gao Y, Zhang P, Chu Q (2021) Acquired Resistance to Immune Checkpoint blockades: the underlying mechanisms and potential strategies. Front Immunol 12:693609 Published 2021 Jun 14. https:\/\/doi.org\/10.3389\/fimmu.2021.693609","journal-title":"Front Immunol"},{"issue":"1","key":"4689_CR9","doi-asserted-by":"publisher","first-page":"e000398","DOI":"10.1136\/jitc-2019-000398","volume":"8","author":"HM Kluger","year":"2020","unstructured":"Kluger HM, Tawbi HA, Ascierto ML et al (2020) Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. J Immunother Cancer 8(1):e000398. https:\/\/doi.org\/10.1136\/jitc-2019-000398","journal-title":"J Immunother Cancer"},{"issue":"7749","key":"4689_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT et al (2019) Neoantigen-Directed Immune escape in Lung Cancer Evolution. Nature 567(7749):479\u2013485. https:\/\/doi.org\/10.1038\/s41586-019-1032-7","journal-title":"Nature"},{"issue":"2","key":"4689_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/medsci7020014","volume":"7","author":"T Seto","year":"2019","unstructured":"Seto T, Sam D, Pan M (2019) Mechanisms of primary and secondary resistance to Immune checkpoint inhibitors in Cancer. Med Sci (Basel) 7(2):14. https:\/\/doi.org\/10.3390\/medsci7020014. Published 2019 Jan 22","journal-title":"Med Sci (Basel)"},{"key":"4689_CR12","doi-asserted-by":"publisher","unstructured":"Bixby D, Talpaz M (2009) Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to Overcome Resistance. Hematol Am Soc Hematol Educ Program 461\u2013476. https:\/\/doi.org\/10.1182\/asheducation-2009.1.461","DOI":"10.1182\/asheducation-2009.1.461"},{"key":"4689_CR13","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","volume":"15","author":"D Milojkovic","year":"2009","unstructured":"Milojkovic D, Apperley J (2009) Mechanisms of resistance to Imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res off J Am Assoc Cancer Res 15:7519\u20137527. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1068","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res"},{"key":"4689_CR14","doi-asserted-by":"publisher","first-page":"22811","DOI":"10.3390\/ijms160922811","volume":"16","author":"M Polillo","year":"2015","unstructured":"Polillo M, Galimberti S, Barat\u00e8 C, Petrini M, Danesi R, Di Paolo A (2015) Pharmacogenetics of BCR\/ABL inhibitors in chronic myeloid leukemia. Int J Mol Sci 16:22811\u201322829. https:\/\/doi.org\/10.3390\/ijms160922811","journal-title":"Int J Mol Sci"},{"key":"4689_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/OTT.S289306","volume":"15","author":"S De Santis","year":"2022","unstructured":"De Santis S, Monaldi C, Mancini M, Bruno S, Cavo M, Soverini S (2022) Overcoming resistance to kinase inhibitors: the paradigm of chronic myeloid leukemia. OncoTargets Ther 15:103\u2013116. https:\/\/doi.org\/10.2147\/OTT.S289306","journal-title":"OncoTargets Ther"},{"key":"4689_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/humu.21159","volume":"31","author":"NPC Santos","year":"2010","unstructured":"Santos NPC, Ribeiro-Rodrigues EM, Ribeiro-Dos-Santos AKC, Pereira R, Gusm\u00e3o L, Amorim A, Guerreiro JF, Zago MA, Matte C, Hutz MH et al (2010) Assessing individual interethnic admixture and Population substructure using a 48-Insertion-deletion (INSEL) ancestry-informative marker (AIM) Panel. Hum Mutat 31:184\u2013190. https:\/\/doi.org\/10.1002\/humu.21159","journal-title":"Hum Mutat"},{"key":"4689_CR17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41397-020-00200-w","volume":"21","author":"G Suarez-Kurtz","year":"2021","unstructured":"Suarez-Kurtz G (2021) Population Impact of Pharmacogenetic tests in Admixed populations across the Americas. Pharmacogenomics J 21:216\u2013221. https:\/\/doi.org\/10.1038\/s41397-020-00200-w","journal-title":"Pharmacogenomics J"},{"key":"4689_CR18","doi-asserted-by":"publisher","first-page":"7201","DOI":"10.1038\/s41598-019-43610-y","volume":"9","author":"JCG Rodrigues","year":"2019","unstructured":"Rodrigues JCG, Fernandes MR, Guerreiro JF, da Silva ALdaC, Ribeiro-Dos-Santos \u00c2, Santos S, Santos NPCD (2019) Polymorphisms of ADME-Related genes and their implications for drug safety and efficacy in amazonian amerindians. Sci Rep 9:7201. https:\/\/doi.org\/10.1038\/s41598-019-43610-y","journal-title":"Sci Rep"},{"key":"4689_CR19","doi-asserted-by":"publisher","first-page":"10292","DOI":"10.1038\/s41598-020-67312-y","volume":"10","author":"DC de Carvalho","year":"2020","unstructured":"de Carvalho DC, Wanderley AV, Dos Santos AMR, Moreira FC, de S\u00e1 RBA, Fernandes MR, Modesto AAC, de Souza TP, Cohen-Paes A, Leit\u00e3o LPC et al (2020) Characterization of pharmacogenetic markers related to Acute Lymphoblastic Leukemia toxicity in amazonian native americans Population. Sci Rep 10:10292. https:\/\/doi.org\/10.1038\/s41598-020-67312-y","journal-title":"Sci Rep"},{"key":"4689_CR20","doi-asserted-by":"publisher","first-page":"696960","DOI":"10.3389\/fphar.2021.696960","volume":"12","author":"M Kaehler","year":"2021","unstructured":"Kaehler M, Cascorbi I (2021) Pharmacogenomics of impaired tyrosine kinase inhibitor response: lessons learned from chronic myelogenous leukemia. Front Pharmacol 12:696960. https:\/\/doi.org\/10.3389\/fphar.2021.696960","journal-title":"Front Pharmacol"},{"key":"4689_CR21","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1158\/1078-0432.ccr-0785-3","volume":"10","author":"MA Dressman","year":"2004","unstructured":"Dressman MA, Malinowski R, McLean LA, Gathmann I, Capdeville R, Hensley M, Polymeropoulos MH (2004) International Randomized Study of Interferon-alpha versus ST1571 Study Group correlation of Major Cytogenetic Response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with Imatinib (STI571). Clin Cancer Res off J Am Assoc Cancer Res 10:2265\u20132271. https:\/\/doi.org\/10.1158\/1078-0432.ccr-0785-3","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res"},{"key":"4689_CR22","doi-asserted-by":"publisher","unstructured":"Cereja Pantoja KBC, de B. Azevedo TC, de Carvalho DC, Monte N, Cohen Paes AdeN, Barros MCdaC, Vinagre LWMS, Freitas ARSde, Burbano RMR, Assump\u00e7\u00e3o PPde et al (2022) Impact of variants in the ATIC and ARID5B genes on therapeutic failure with Imatinib in patients with chronic myeloid leukemia. Genes 13(330). https:\/\/doi.org\/10.3390\/genes13020330","DOI":"10.3390\/genes13020330"},{"key":"4689_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.2012.066480","volume":"98","author":"S Angelini","year":"2013","unstructured":"Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, Pane F, Hughes TP, White DL, Radich J et al (2013) Association between Imatinib Transporters and Metabolizing Enzymes Genotype and response in newly diagnosed chronic myeloid leukemia patients receiving Imatinib Therapy. Haematologica 98:193\u2013200. https:\/\/doi.org\/10.3324\/haematol.2012.066480","journal-title":"Haematologica"},{"key":"4689_CR24","doi-asserted-by":"publisher","unstructured":"Delmond KA, Delleon H, Goveia RM, Teixeira TM, Abreu DC, Mello-Andrade F, Reis AA, da Silva S, de Barbosa D, Tavares A et al (2021) R.S.;. Influence of Genetic Polymorphisms in Glutathione-S-Transferases Gene in Response to Imatinib among Brazilian Patients with Chronic Myeloid Leukemia. Mol. Biol. Rep. 48, 2035\u20132046, https:\/\/doi.org\/10.1007\/s11033-020-06093-z","DOI":"10.1007\/s11033-020-06093-z"},{"key":"4689_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cancergencyto.2005.01.015","volume":"162","author":"S Galimberti","year":"2005","unstructured":"Galimberti S, Cervetti G, Guerrini F, Testi R, Pacini S, Fazzi R, Simi P, Petrini M (2005) Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib Treatment. Cancer Genet Cytogenet 162:57\u201362. https:\/\/doi.org\/10.1016\/j.cancergencyto.2005.01.015","journal-title":"Cancer Genet Cytogenet"},{"key":"4689_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/tpj.2014.54","volume":"15","author":"Q Zheng","year":"2015","unstructured":"Zheng Q, Wu H, Yu Q, Kim DHD, Lipton JH, Angelini S, Soverini S, Vivona D, Takahashi N, Cao J (2015) ABCB1 polymorphisms Predict Imatinib response in chronic myeloid leukemia patients: a systematic review and Meta-analysis. Pharmacogenomics J 15:127\u2013134. https:\/\/doi.org\/10.1038\/tpj.2014.54","journal-title":"Pharmacogenomics J"},{"key":"4689_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5045\/br.2019.54.1.57","volume":"54","author":"AML Bedewy","year":"2019","unstructured":"Bedewy AML, Elmaghraby SM, Kandil NS (2019) ABCB1 and BMI1 MRNA expression in patients with chronic myeloid leukemia: impact on Imatinib Efficacy. Blood Res 54:57\u201362. https:\/\/doi.org\/10.5045\/br.2019.54.1.57","journal-title":"Blood Res"},{"key":"4689_CR28","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3390\/pharmaceutics14040878","volume":"14","author":"JE Meg\u00edas-Vericat","year":"2022","unstructured":"Meg\u00edas-Vericat JE, Mart\u00ednez-Cuadr\u00f3n D, Solana-Altabella A, Poveda JL, Montesinos P (2022) Systematic review of pharmacogenetics of ABC and SLC Transporter genes in Acute myeloid leukemia. Pharmaceutics 14:878. https:\/\/doi.org\/10.3390\/pharmaceutics14040878","journal-title":"Pharmaceutics"},{"key":"4689_CR29","doi-asserted-by":"publisher","unstructured":"Song Y, Chen J, Liu K, Zhou K, Lu Y, Wang X, Yang Y, Liu X, Glutathione S-Transferase Pi 1 (GSTP1) Gene 313 A\/G (Rs1695) Polymorphism Is Associated with the Risk of Urinary Bladder Cancer: Evidence from a Systematic Review and Meta-Analysis Based on 34 Case-Control Studies (2019) Gene 719:144077. https:\/\/doi.org\/10.1016\/j.gene.2019.144077","DOI":"10.1016\/j.gene.2019.144077"},{"key":"4689_CR30","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s12041-017-0819-2","volume":"96","author":"SM Makhtar","year":"2017","unstructured":"Makhtar SM, Husin A, Baba AA, Ankathil R (2017) Association of GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms with clinical response to Imatinib Mesylate Treatment among Malaysian chronic myeloid leukaemia patients. J Genet 96:633\u2013639. https:\/\/doi.org\/10.1007\/s12041-017-0819-2","journal-title":"J Genet"},{"key":"4689_CR31","doi-asserted-by":"publisher","first-page":"e00717","DOI":"10.1002\/mgg3.717","volume":"7","author":"G Rostami","year":"2019","unstructured":"Rostami G, Assad D, Ghadyani F, Hamid M, Karami A, Jalaeikhoo H, Kalahroodi RA (2019) Influence of glutathione S-Transferases (GSTM1, GSTT1, and GSTP1) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response. Mol Genet Genomic Med 7:e00717. https:\/\/doi.org\/10.1002\/mgg3.717","journal-title":"Mol Genet Genomic Med"},{"key":"4689_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2012.10.015","volume":"68","author":"S Angelini","year":"2013","unstructured":"Angelini S, Pantaleo MA, Ravegnini G, Zenesini C, Cavrini G, Nannini M, Fumagalli E, Palassini E, Saponara M, Di Battista M et al (2013) Polymorphisms in OCTN1 and OCTN2 transporters genes are Associated with prolonged time to Progression in Unresectable gastrointestinal stromal tumours treated with Imatinib Therapy. Pharmacol Res 68:1\u20136. https:\/\/doi.org\/10.1016\/j.phrs.2012.10.015","journal-title":"Pharmacol Res"},{"key":"4689_CR33","doi-asserted-by":"publisher","first-page":"e78582","DOI":"10.1371\/journal.pone.0078582","volume":"8","author":"V Augis","year":"2013","unstructured":"Augis V, Airiau K, Josselin M, Turcq B, Mahon F-X, Belloc FA (2013) Single nucleotide polymorphism in CBIM is Associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with Imatinib. PLoS ONE 8:e78582. https:\/\/doi.org\/10.1371\/journal.pone.0078582","journal-title":"PLoS ONE"},{"key":"4689_CR34","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.leukres.2012.07.003","volume":"36","author":"M Tsubaki","year":"2012","unstructured":"Tsubaki M, Satou T, Itoh T, Imano M, Komai M, Nishinobo M, Yamashita M, Yanae M, Yamazoe Y, Nishida S (2012) Overexpression of MDR1 and Survivin, and decreased Bim expression mediate Multidrug-Resistance in multiple myeloma cells. Leuk Res 36:1315\u20131322. https:\/\/doi.org\/10.1016\/j.leukres.2012.07.003","journal-title":"Leuk Res"},{"key":"4689_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/jpm7040018","volume":"7","author":"J-A Tanner","year":"2017","unstructured":"Tanner J-A, Tyndale RF (2017) Variation in CYP2A6 activity and Personalized Medicine. J Pers Med 7:18. https:\/\/doi.org\/10.3390\/jpm7040018","journal-title":"J Pers Med"},{"key":"4689_CR36","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/em.22466","volume":"62","author":"VK Yadav","year":"2021","unstructured":"Yadav VK, Katiyar T, Ruwali M, Yadav S, Singh S, Hadi R, Bhatt MLB, Parmar D (2021) Polymorphism in cytochrome P4502A6 reduces the risk to Head and Neck Cancer and modifies the treatment outcome. Environ Mol Mutagen 62:502\u2013511. https:\/\/doi.org\/10.1002\/em.22466","journal-title":"Environ Mol Mutagen"},{"key":"4689_CR37","doi-asserted-by":"publisher","first-page":"104234","DOI":"10.1016\/j.phrs.2019.04.018","volume":"154","author":"A Jetter","year":"2020","unstructured":"Jetter A, Kullak-Ublick GA (2020) Drugs and hepatic transporters: a review. Pharmacol Res 154:104234. https:\/\/doi.org\/10.1016\/j.phrs.2019.04.018","journal-title":"Pharmacol Res"},{"key":"4689_CR38","doi-asserted-by":"publisher","first-page":"6887","DOI":"10.1007\/s00018-021-03901-y","volume":"78","author":"S Kukal","year":"2021","unstructured":"Kukal S, Guin D, Rawat C, Bora S, Mishra MK, Sharma P, Paul PR, Kanojia N, Grewal GK, Kukreti S et al (2021) Multidrug Efflux Transporter ABCG2: expression and regulation. Cell Mol Life Sci 78:6887\u20136939. https:\/\/doi.org\/10.1007\/s00018-021-03901-y","journal-title":"Cell Mol Life Sci"},{"key":"4689_CR39","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.18632\/oncotarget.1050","volume":"4","author":"M Delord","year":"2013","unstructured":"Delord M, Rousselot P, Cayuela J-M, Sigaux F, Guilhot J, Preudhomme C, Guilhot F, Loiseau P, Raffoux E, Geromin D et al (2013) High Imatinib Dose overcomes Insufficient Response Associated with ABCG2 haplotype in chronic myelogenous leukemia patients. Oncotarget 4:1582\u20131591. https:\/\/doi.org\/10.18632\/oncotarget.1050","journal-title":"Oncotarget"},{"key":"4689_CR40","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1080\/15257770802145892","volume":"27","author":"AV Leisewitz","year":"2008","unstructured":"Leisewitz AV, Zimmerman EI, Jones SZ, Yang J, Graves LM, Imatinib-Resistant CML (2008) Cells have low ENT Activity but maintain sensitivity to Gemcitabine. Nucleosides Nucleotides Nucleic Acids 27:779\u2013786. https:\/\/doi.org\/10.1080\/15257770802145892","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"4689_CR41","doi-asserted-by":"publisher","first-page":"18809","DOI":"10.1074\/jbc.M116.741074","volume":"291","author":"VL Damaraju","year":"2016","unstructured":"Damaraju VL, Weber D, Kuzma M, Cass CE, Sawyer MB (2016) Selective inhibition of human equilibrative and concentrative nucleoside transporters by BCR-ABL kinase inhibitors: IDENTIFICATION OF KEY HENT1 AMINO ACID RESIDUES FOR INTERACTION WITH BCR-ABL KINASE INHIBITORS *. J Biol Chem 291:18809\u201318817. https:\/\/doi.org\/10.1074\/jbc.M116.741074","journal-title":"J Biol Chem"},{"key":"4689_CR42","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1248\/bpb.b12-00809","volume":"36","author":"Y Suzuki","year":"2013","unstructured":"Suzuki Y, Homma M, Abei M, Hyodo I, Kohda Y (2013) Impact of Solute Carrier Family 29 Member 1 (SLC29A1) single nucleotide polymorphisms on MRNA expression in Peripheral Blood mononuclear cells. Biol Pharm Bull 36:144\u2013146. https:\/\/doi.org\/10.1248\/bpb.b12-00809","journal-title":"Biol Pharm Bull"},{"key":"4689_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2133\/dmpk.DMPK-12-RV-099","volume":"28","author":"IY Gong","year":"2013","unstructured":"Gong IY, Kim RB (2013) Impact of genetic variation in OATP transporters to Drug Disposition and Response. Drug Metab Pharmacokinet 28:4\u201318. https:\/\/doi.org\/10.2133\/dmpk.DMPK-12-RV-099","journal-title":"Drug Metab Pharmacokinet"},{"key":"4689_CR44","doi-asserted-by":"publisher","first-page":"e22513","DOI":"10.1002\/jbt.22513","volume":"34","author":"J Wang","year":"2020","unstructured":"40, Wang J, Yin J, Li W, Xiao C, Han J, Zhou F (2020) Association between SLCO1A2 Genetic Variation and Methotrexate Toxicity in Human Rheumatoid Arthritis Treatment. J Biochem Mol Toxicol 34:e22513. https:\/\/doi.org\/10.1002\/jbt.22513","journal-title":"J Biochem Mol Toxicol"},{"key":"4689_CR45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/clpt.2011.102","volume":"90","author":"Y Yamakawa","year":"2011","unstructured":"Yamakawa Y, Hamada A, Shuto T, Yuki M, Uchida T, Kai H, Kawaguchi T, Saito H (2011) Pharmacokinetic impact of SLCO1A2 polymorphisms on Imatinib Disposition in patients with chronic myeloid leukemia. Clin Pharmacol Ther 90:157\u2013163. https:\/\/doi.org\/10.1038\/clpt.2011.102","journal-title":"Clin Pharmacol Ther"},{"key":"4689_CR46","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","volume":"18","author":"MW Deininger","year":"2020","unstructured":"Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, DeAngelo DJ, Gotlib J, Hobbs G, Maness L et al (2020) Chronic myeloid leukemia, Version 2.2021. JNCCN J Natl Compr Cancer Netw 18:1385\u20131415. https:\/\/doi.org\/10.6004\/jnccn.2020.0047","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"key":"4689_CR47","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"key":"4689_CR48","unstructured":"Oeth P, Beaulieu M, Park C, Kosman D (2005) IPLEX\u2122 Assay: Increased Plexing Efficiency and Flexibility for MassARRAY System Through Single Base Primer Extension with Mass-Modified Terminators"},{"key":"4689_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/b978-0-12-385855-9.00001-1","volume":"53","author":"K Meyer","year":"2011","unstructured":"Meyer K, Ueland PM (2011) Use of Matrix-assisted laser Desorption\/Ionization time-of-flight Mass Spectrometry for Multiplex genotyping. Adv Clin Chem 53:1\u201329. https:\/\/doi.org\/10.1016\/b978-0-12-385855-9.00001-1","journal-title":"Adv Clin Chem"},{"key":"4689_CR50","doi-asserted-by":"publisher","unstructured":"Ramos BR, de Mendes A, Tanikawa ND, Amador AA, dos Santos MAT, dos Santos NPC, Castelli SEB, Witkin EC, da Silva SS (2016) Ancestry informative markers and selected single nucleotide polymorphisms in Immunoregulatory genes on Preterm Labor and Preterm premature rupture of membranes: a Case Control Study. BMC Pregnancy Childbirth 16. https:\/\/doi.org\/10.1186\/s12884-016-0823-1","DOI":"10.1186\/s12884-016-0823-1"},{"key":"4689_CR51","doi-asserted-by":"publisher","unstructured":"Santos NP, Ribeiro-Rodrigues EM, Ribeiro-Dos-Santos AK, Pereira R, Gusm\u00e3o L, Amorim A, Guerreiro JF, Zago MA, Matte C, Hutz MH, Santos SE (2010) Assessing individual interethnic admixture and population substructure using a 48-insertion-deletion (INSEL) ancestry-informative marker (AIM) panel. Hum Mutat. 31(2):184\u2009\u2013\u200990. https:\/\/doi.org\/10.1002\/humu.21159. PMID: 19953531","DOI":"10.1002\/humu.21159"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04689-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04689-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04689-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T19:02:44Z","timestamp":1727118164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04689-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["4689"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04689-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]},"assertion":[{"value":"9 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the research ethics committee of the N\u00facleo de Pesquisas em Oncologia (protocol number 3.354.571\/2019) and by the Ophir Loyola Hospital (protocol number 1.575.920\/2016). Informed consent Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"The authors report no declarations of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}